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Introduction
Hepatocellular carcinoma (HCC) is the third most deadly type of cancer globally [1] . The high mortality rate of HCC is related mainly to late diagnosis at advanced stages, frequent tumor metastasis, and tumor recurrence after surgical resection [2] . Metastasis is the principal cause of tumor recurrence but promising therapy for HCC metastasis is not HCC metastasis.
Metastasis represents the last process of a multistep cell-biological process, including dissemination of cancer cells to anatomically distant organ and their subsequent adaptation to foreign tissue microenvironments [3] . As a barrier to metastasis, cells normally undergo an apoptotic process known as anoikis, a form of programmed cell death induced by loss of contact with the extracellular matrix or neighboring cells. Cancer cells acquire anoikis resistance to survive after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body. Anoikis resistance is a critical step in tumor metastasis [4] .
Caveolin-1 (CAV1), a 21-24 kDa lipid raft-associated membrane protein and an essential constituent of caveolae, could play critical roles in several cellular processes including vesicular transport, cholesterol homeostasis and anoikis [5, 6] . CAV1 belongs to a highly conserved gene family named caveolins and is coexpressed with caveolin-2 in the cells and tissues of various origins including mesenchymal, endo/epithelial, and neuronal/glial [7] . Recently, substantial evidence has indicated that CAV1 is implicated in progression and metastasis of diverse human tumors such as meningiomas [8] , bladder cancer [9] , esophageal squamous cell carcinoma [10], mammary cancer [11], colon cancer [12] and osteosarcomas [13] .
In HCC, CAV1 was reported to be related to vascular endothelial growth factor, microvessel density and unpaired artery [14] . Increased expression of CAV1 promoted carcinogenesis and metastasis of HCC in vitro and in vivo [15] . CAV1 could facilitate metastasis of HCC cells
However, the precise molecular mechanism of CAV1 in anoikis resistance of HCC has not resistance of HCC and the underlying mechanism.
Materials and Methods

Ethics statement
Ethical approval for human subjects was obtained from the Research Ethics Committee of Zhongshan Hospital, and informed consent was obtained from each patient.
Patients and tissue specimens
Tumor specimens were obtained from 120 consecutive patients with HCC who underwent curative resection at the Liver Cancer Institute, Zhongshan Hospital, Fudan University in 2009.
Antibodies
Primary antibodies against Caveolin-1 (D46G3, #3267), Akt (pan) (C67E7, #4691), phospho-Akt (Ser473) (D9E, #4060), Erk1/2 (137F5, #4695), phospho-Erk1/2 (D13.14.4E, #4370), Bcl-2 (50E3, #2870), Bcl-xl (54H6, #2764) and Mcl-1 (D35A5, #5453) were purchased from Cell Signaling Technology (Beverly, MA), Caveolin-1 (Y14) antibody antibody was produced by immunization of rabbits with recombinant Y14 phosphate dehydrogenase (GAPDH) (0411, sc-47724) was from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary antibodies conjugated with HRP were from Jackson ImmunoResearch Laboratories (West Grove, PA). 
Western blot, colony formation and apoptosis assay
Western blot, soft agar colony formation and apoptosis assay were performed as described previously [18, 19] .
Anoikis assay
overnight, centrifuged at 2,500 rpm to remove undissolved particles, and diluted 1:10 with 95% ethanol. 100-mm dishes were coated with 4 ml of poly-HEMA solution and left to dry at room temperature. Dishes were washed twice with PBS and once with HBSS before use. Then the cells were cultured for 48 hours before in vitro assays.
TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed by using in situ cell death detection kit (Roche Applied Science, Indianapolis, IN, USA) according to manufacturer's instructions.
Caspase-3 and caspase-9 activity assay caspase-3/7 assay kit and Caspase-Glo 9 assay kit (Promega, WI, USA) according to the manufacturer's instructions.
Transmission electron microscopy
with 2.5% glutaraldehyde with 0.1 mol/L sodium cacodylate and stored at 4°C until embedding. Samples gradient of ethanol and propylene oxide. Samples were then embedded and ultrathin (50-60 nm) sections were cut using an ultramicrotome. Images were examined using a JEM-1200 electron microscope at 80 kV after the samples were stained with 3% uranyl acetate and lead citrate.
I IGF1 internalization assay
125
I IGF1 internalization assay was conducted as previously described [23] . Cells (2×10 5 ) plated on 40-mm gelatinized plates were incubated with Krebs-Ringer phosphate HEPES binding buffer (KRPHBB) , pH I IGF1 for 0 to 120 min, rinsed, and washed in KRPHBB (pH 3.5) for 10 min at 37°C to remove surface-bound IGF1. This internalized IGF1. All values were standardized against protein content. The internalization rate constant K e , represented by the slope of the line correlating the internalized to surface bound IGF, was calculated by linear regression [24, 25] .
Site-directed mutagenesis and cell transfection
Transfection assays were performed using Lipofectamine LTX and Plus Reagent (Invitrogen, USA) according to the manufacturer's protocol. Short interfering RNAs (siRNA) target sequence to human IGF-1R (GenBank: NM_000875) (si-IGF-1R, 5'-GCC GAT GTG TGA GA AGC -3') were synthesized by GenePharma (Shanghai, China). Site-directed mutagenesis was performed to construct pCMV6-CAV1/ Y14F by the QuickChange mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The oligonucleotide primers were as follows: 5´-GGACATCTCTTCACTGTTCCC-3´ and 5´-GGGAACAGTGA sequencing analysis.
Immunohistochemistry and immunohistochemical staining
series diluted in distilled water. Following antigen retrieval with a 10 mM citrate buffer, HCC sections were incubated overnight at 4°C with primary antibody. Following 30 min incubation with secondary antibody, sections were developed in 3, 3'-diaminobenzidine solution under microscopic observation and counterstained with hematoxylin.
The sections were observed under a light microscopy, for a histological review, to examine tumor each section were observed and scored. A semi-quantitative scoring system was based on both the staining intensity (0, negative; 1, weak; 2, intermediate; 3, strong) and the percentage of positive cells (0, 0% positive was obtained by multiplying the scores of staining intensity and percentage of positive cells. Samples were staining was carried out by two independent pathologists.
Statistical analysis
GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA) software was used for statistical analyses. All data are presented as mean ± standard deviation (SD) from three independent experiments. Continuous variables were compared using the Student's t-test. All tests were two-tailed and a P value < 0.05 was determined by Pearson correlation analysis.
Results
CAV1 promoted anchorage independent growth and anoikis resistance in hepatoma cells
with high metastatic potential) but not in Hep3B (a non-metastatic HCC cell line) [16, 26] . In this study, to further examine the function of CAV1 in HCC development, we established one stable CAV1-expression clone in Hep3B cells and two stable CAV1-knockdown clones in MHCC97H cells. Enhanced CAV1 expression (> 2-fold) in Hep3B and suppressed CAV1 is a prerequisite for acquisition of anchorage-independent growth in malignant cells [27] , we thus proposed that the difference of anchorage-independent growth between groups To test this hypothesis, we examined the effect of CAV1 on cell suspension conditions. Hepatoma cells were plated on non-adhesive poly-HEMA for 72 h. CAV1-overexpression showed marked anoikis resistance, while its knockdown promoted apoptosis as detected by Annexin V staining ( Fig. 1C and Fig. 1D ). Similarly, CAV1-overexpression cells were found to undergo less anoikis than the control, whereas CAV1-knockdown cells showed more apoptosis compared with the control as indicated by TUNEL assay (Fig. 1E and Fig. 1F ). In accordance with this phenomenon, caspase-3 and caspase-9 activity was decreased in CAV1-overexpression cells and increased in CAV1-knockdown cells ( Fig. 2A and Fig. 2B ).
CAV1 promoted anchorage-independent growth and anoikis resistance by activating IGF-1 receptor pathway
The above results indicated that CAV1 promoted anchorage-independent growth and anoikis resistance in hepatoma cells. Since CAV1 has been reported to interact directly with insulin-like growth factor-1 receptor (IGF-1R) [28], we examined the expression of IGF1R and its two major downstream signaling pathways: the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the RAF/MEK/ERK pathway which were closely related to anoikis resistance [29] . The result of Western blotting showed that the expression of IGF-1R, phosphor-Akt (Ser473) and phosphor-ERK1/2 was remarkably increased in CAV1-overexpression cells versus the control (Fig. 3A and 3C ). In addition, we detected the key molecules of apoptosis Cellular Physiology and Biochemistry signal pathway and found that the expression of antiapoptotic Bcl-2 and Mcl-1 was obviously decreased in CAV1-overexpression comparing to the control. However, there was no difference of antiapoptotic Bcl-xL expression between groups ( Fig. 3B and 3D ).
CAV1 promoted caveolae invagination and IGF-1R internalization in hepatoma cells
To further explore the reason for CAV1-induced IGF-1R activation, we detected the effect of CAV1 on caveolae internalization. The result of electron microscopy showed that CAV1-overexpression increased the number of invaginated caveolae while CAV1-knockdown (Fig. 4C) . However, CAV1-knockdown showed the opposite effect (Fig. 4D) . The ratio of internalized to surface bound 125 I-IGF-1 was larger in CAV1-overexpression cells than the control, while less in CAV1-knockdown cells than the control (Fig. 4E-F) . These data indicated CAV1 could promote caveolae internalization and 125 I-IGF-1R internalization, thus activating IGF-1R pathway. 
CAV1 mediated anchorage-independent growth, anoikis resistance and caspases inhibition in hepatoma cells through the function of its tyrosine-14 residue and IGF-1R
Since tyrosine-14 (Y14) residue was a crucial phosphorylation site required for CAV1 functions [30, 31] , we conducted a caveolin-1 mutant containing tyrosine 14 substituted with phenylalanine (CAV1/Y14F). In addition, we used Y14 antibody to examine the role of Y14 residue on CAV1-mediated oncogenic behaviors. Moreover, we used IGF-1R siRNA to study the role of IGF-1R on CAV1-mediated tumor-promoting effect. The result showed that increased anchorage-independent growth caused by CAV1-overexpresssion was reversed by Y14 mutation, Y14 antibody and IGF-1R interference (Fig. 5A and 5B). Similarly, suppressed anoikis and decreased caspase-3/9 activity caused by CAV1-overexpresssion was rescued by Y14 mutation, Y14 antibody and IGF-1R interference (Fig.5C and 5D, Fig. 6A and 6B ).
CAV1 expression was positively related to IGF-1R expression in human HCC tissues
To further explore the correlation of CAV1 with IGF-1R, we performed samples. The result showed that CAV1 and IGF-1R was mainly located in cell membrane and cytoplasm (Fig. 7A) . Survival analysis showed that CAV1 expression in tumor tissue was (Fig. 7B) . Evaluation of immunohistochemistry staining and correlation analysis indicated that CAV1 expression level was positively related to IGF-1R expression in HCC tissues (R = 0.5403, P = 0.0003) (Fig.  7C ).
Discussion
most normal epithelial and mesenchymal cells for extracellular matrix-derived signals of survival. The acquisition of anoikis-resistance is therefore regarded as a critical step during the metastatic transformation of a tumor [32, 33] . CAV1 was reported to correlate with anoikis in a variety of cancers. CAV1 expression decreased capacities of anchorageindependent growth and anoikis in MCF-7 breast cancer cells [34] . CAV1 mediated anoikis resistance through regulating Mcl-1 interaction and stabilization in lung cancer cells [35] . However, to date it has remained unclear whether CAV1 inhibited or promoted anoikis CAV1 in anoikis of hepatoma cells and underlying mechanisms. We observed that CAV1 over- and promote anchorage-independent growth. CAV1 overexpression also decreased the activity of caspases-3 and 9 during anoikis. As expected, CAV1 knockdown showed the opposite effect in vitro which was in accordance with our previous study [16] . IGF-1R signaling frequently mediated anoikis resistance in diverse malignant cells [36, 37] . As two major downstream signaling pathways of IGF-1R signaling, phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the RAF/MEK/ERK pathway was closely correlated with has been demonstrated in Ewing family of tumors cell lines [38] . IGF-1R-promoted anoikis resistance via Akt and ERK1/2 phosphorylation has been reported in breast cancer cells IGF-1R, p-Akt and p-ERK1/2 in hepatoma cells, indicating the activation of IGF-1 pathway anchorage-independent growth and anoikis resistance caused by CAV1 overexpression.
resistance to hepatoma cells through IGF-1R pathway.
Internalization is a mechanism by which receptor tyrosine kinases (RTKs) leave the of these processes can be altered in cancer cells [39] . Regulated alternation in caveolae number and dynamics has been reported to correlate closely with the internalization of a variety of RTKs like epithelial Growth Factor and vascular endothelial growth factor [40, 41] . CAV1 is essential for the formation and stability of caveolae, which is directly involved explained how CAV1 activate IGF-1R signaling pathway in hepatoma cells. Tyrosine-14 (Y14) residue of CAV1, a target site for phosphorylation by the non-receptor tyrosine kinases, played important roles in a variety of CAV1-mediated physiological and pathologic processes [43] . EGF-stimulated Y14 phosphorylation promoted caveolae formation in epithelial cells [44] . Y14 phosphorylation following LPS exposure induced the interaction between CAV1 endothelial cells [45] . Y14 phosphorylation also sensitized breast cancer cells to paclitaxel through inactivating Bcl-2 and Bcl-xL [46] . Based on these studies, we supposed that Y14 site may play an important role in the anoikis resistance mediated by CAV1. In the present antibody. The data showed that anoikis resistance caused by CAV1 could be remarkably interference in antagonizing CAV-mediated the oncogenic behaviors and provided a new potential treatment strategy for HCC. CAV1 has aroused great interest and has been extensively studied in cancer development and progression. With respect to HCC, CAV1 was upregulated in HCC cell lines, especially in highly invasive HCC cell lines. CAV1 overexpression has been shown to correlate with the incidence of metastasis and poor prognosis in HCC patients [14, 15, 47] . CAV1 increased HepG2 hepatoma cells [48] . CAV1 upregulated the expression of Twist, a well-known EMT previous study revealed that CAV1 could facilitate carcinogenesis and metastasis of HCC via clues to understand the role of CAV1 in HCC.
In conclusion, these results suggest that CAV1 confer resistance of hepatoma cells to anoikis by activating IGF-1 pathway, via facilitating caveolae invagination and IGF-1R 
